Needham analyst David Saxon reiterated a Buy rating on Alcon on August 20 and set a price target of $107.00.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
David Saxon has given his Buy rating due to a combination of factors including Alcon’s performance and market position. Despite a slight miss in revenue expectations for the second quarter of 2025, Alcon’s earnings per share exceeded predictions, aided by a favorable tax situation. This indicates a robust financial management strategy that maintains profitability even in challenging market conditions.
Additionally, while the company adjusted its revenue guidance downward due to anticipated slower market growth, it upheld its earnings per share forecast, suggesting confidence in its operational efficiency and cost management. Furthermore, Alcon’s market share in the contact lens sector has shown year-over-year growth, reinforcing its competitive position in the industry. These elements collectively support Saxon’s positive outlook on Alcon’s stock.
According to TipRanks, Saxon is an analyst with an average return of -0.4% and a 35.97% success rate. Saxon covers the Healthcare sector, focusing on stocks such as Alcon, Cooper Co, and DENTSPLY SIRONA.
In another report released yesterday, Bank of America Securities also reiterated a Buy rating on the stock with a CHF80.00 price target.